Sean Amirzadeh, DO
Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1801328927
Payments from drug & device makers
Across 272 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$576
- BETA Bionics, Inc.$394
- Bayer$282
- Ultragenyx Pharmaceutical Inc.$280
- Dexcom, Inc.$230
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,202 |
| Lilly USA, LLC | 36 | $576 |
| BETA Bionics, Inc. | 11 | $394 |
| Bayer | 14 | $282 |
| Ultragenyx Pharmaceutical Inc. | 2 | $280 |
| Dexcom, Inc. | 8 | $230 |
| AbbVie | 11 | $202 |
| Sanofi-aventis U.S. LLC | 9 | $193 |
| Xeris Pharmaceuticals, Inc. | 9 | $173 |
| Recordati_rare_diseases_inc. | 8 | $167 |
| Abbott | 9 | $163 |
| Avvisto Therapeutics, LLC | 7 | $134 |
| Corcept Therapeutics | 6 | $134 |
| Amgen | 6 | $121 |
| Insulet Corporation | 6 | $118 |
| Tandem Diabetes Care, Inc. | 6 | $116 |
| Amneal Pharmaceuticals LLC | 6 | $113 |
| Boehringer Ingelheim | 5 | $101 |
| Madrigal Pharmaceuticals | 3 | $78 |
| Sequel Med Tech, LLC | 3 | $65 |
| Radius Health, Inc. | 3 | $61 |
| Ascendis Pharma Endocrinology Inc | 2 | $52 |
| Renalytix AI, Inc. | 2 | $50 |
| Nevro Corp. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Merck | 2 | $34 |
| Antares Pharma, Inc. | 2 | $32 |
| Medtronic | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Echosens North America, Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Boston Scientific | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$368
- CRYSVITA$280
How this compares
$5,341 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 298 | $500,997 |
| MounjaroTirzepatide | 224 | $318,014 |
| JardianceEmpagliflozin | 136 | $151,038 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $65,992 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $44,990 |
| FarxigaDapagliflozin Propanediol | 27 | $28,276 |
| Humalog Kwikpen U-100Insulin Lispro | 65 | $26,837 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $24,130 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 157 | $23,180 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $22,324 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $19,019 |
| Novolog FlexpenInsulin Aspart | 97 | $18,585 |
| Gvoke Hypopen 2-PackGlucagon | 22 | $15,847 |
| TrulicityDulaglutide | 15 | $14,703 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $14,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,202 | $510,918322 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $576 | $340,987257 claims |
| Boehringer IngelheimJardiance | $101 | $151,038136 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $193 | $21,48339 claims |
| AbbVieSynthroid | $202 | $7,45077 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $113 | $2,273242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Tampa
- Andrew HenryTampa$929K
- Manuel Sainz de la PenaTampa$247K
- Yuvraj KumbkarniTampa$189K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.